Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India
A Garg, U Batra, P Choudhary, D Jain… - Current Problems in …, 2020 - Elsevier
Background: The development of various targeted therapies against Epidermal Growth
Factor Receptor (EGFR) has been a major step in therapeutic advancements in lung cancer …
Factor Receptor (EGFR) has been a major step in therapeutic advancements in lung cancer …
Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with …
B Chua, EH Tan, DWT Lim, MK Ang… - Annals of …, 2018 - annalsofoncology.org
Background: Treatment options for EGFR mutant advanced/metastatic NSCLC patients
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis
C Buonerba, S Iaccarino, P Dolce, M Pagliuca, M Izzo… - Cancers, 2019 - mdpi.com
Some commonly available patient or disease characteristics may be associated with
progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell …
progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell …
Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
H Wang, J Huang, X Yu, S Han, X Yan, S Sun… - Journal of cancer …, 2014 - Springer
Background Nearly 85% of lung-cancer-specific epidermal growth factor receptor (EGFR)
sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants …
sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants …
Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
H Liu, G Han, M Peng, Y Weng, J Yuan, G Yang… - Current Medical …, 2017 - Springer
With the development of molecular pathology, many types of epidermal growth factor
receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase …
receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase …
[HTML][HTML] Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine …
LC Chang, CK Lim, LY Chang, KY Chen… - European Journal of …, 2019 - Elsevier
Introduction Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or
L858R mutation usually respond to epidermal growth factor receptor–tyrosine kinase …
L858R mutation usually respond to epidermal growth factor receptor–tyrosine kinase …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer
J Fukihara, N Watanabe, H Taniguchi, Y Kondoh… - Oncology, 2014 - karger.com
Background: The presence of EGFR (epidermal growth factor receptor) mutations is a robust
predictor of EGFR tyrosine kinase inhibitor (TKI) responsiveness. Predictors of EGFR-TKI …
predictor of EGFR tyrosine kinase inhibitor (TKI) responsiveness. Predictors of EGFR-TKI …
EGFR mutation-positive lung cancer in real-world treatment outcomes: A multicenter study from Thailand
S Sukauichai, K Maneenil, A Supavavej… - Asian Pacific Journal of …, 2022 - waocp.com
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have
been the standard of care as first-line (1L) therapy for patients with advanced EGFR mutated …
been the standard of care as first-line (1L) therapy for patients with advanced EGFR mutated …
EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized …
CM Zhu, XY Lian, HY Zhang, L Bai… - Journal of Cancer …, 2021 - journals.lww.com
Objective: The objective of this study was to perform a meta-analysis comparing the
efficiency of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with …
efficiency of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with …
相关搜索
- egfr tyrosine kinase inhibitors
- cohort analysis kinase inhibitors
- clinical predictors kinase inhibitors
- cohort analysis egfr tyrosine
- clinical predictors egfr tyrosine
- cohort analysis clinical predictors
- growth factor kinase inhibitors
- lung cancer meta analysis
- lung cancer treatment outcomes
- mutation patterns kinase inhibitors
- egfr mutations retrospective analysis
- egfr mutations growth factor
- receptor tyrosine growth factor
- egfr mutations receptor tyrosine
- egfr mutations clinical parameters
- patients with subtypes meta analysis